Following a full submission.
Voriconazole (Vfend) is accepted for restricted use within NHS Scotland for the treatment of candidaemia in non-neutropenic patients.
Voriconazole provides an additional agent for the treatment of candidaemia in non-neutropenic patients. Its use is restricted to patients with fluconazole-resistant Candida infection who do not respond to, or cannot tolerate amphotericin B therapy or who are at an increased risk of serious side-effects with amphotericin.
Download detailed advice118KB (PDF)
- Medicine name:
- Voriconazole 50mg and 200mg tablets, 40mg/ml oral suspension, and 200mg vials (Vfend®) for infusion
- SMC ID:
- Candidaemia in non-neutropenic patients
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Submission type
- Date advice published
- 08 August 2005